Study shows low risk of CV events with alendronate treatment in patients with hip fracture


eMediNexus    21 May 2018

Alendronate significantly reduces the risk of cardiovascular events (incident myocardial infarction, stroke) and mortality in patients treated with the bisphosphonate following a hip fracture, says a study published online May 9, 2018 in the Journal of Bone and Mineral Research.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.